Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800051 | 0.88 | HRH3 (0.72) | HRH3KCNH2ALDH1A1MMP2MMP3 | |
| SCHEMBL2798202 | 0.88 | HRH3 (0.74) | HRH3KCNH2 | |
| SCHEMBL2799409 | 0.88 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL2797749 | 0.84 | HRH3 (0.69) | HRH3KCNH2 | |
| SCHEMBL2797048 | 0.81 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL2794963 | 0.79 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2800758 | 0.76 | HRH3 (0.69) | HRH3KCNH2 | |
| SCHEMBL2798245 | 0.76 | HRH3 (0.97) | HRH3KCNH2 | |
| SCHEMBL2799780 | 0.75 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL2796990 | 0.75 | HRH3 (1.00) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | claimed |
| EP-2162452-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2010-03-17 | — | — | EP | claimed |
| WO-2008147314-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | claimed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2162452-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008147314-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147314-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | HRH3, HRH2, HRH4 | HRH3 1/4885KCNH2 1140/4885ALDH1A1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.